Avigen, Inc. Reports 2007 Financial Results and Reviews Clinical Progress

ALAMEDA, Calif., Feb. 6, 2008 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today reported financial results for its fourth quarter and full year ended December 31, 2007. At December 31, 2007, Avigen had approximately $78 million in financial assets, including cash, cash equivalents, and available-for-sale securities and restricted investments, compared with approximately $85 million at September 30, 2007 and $71 million at December 31, 2006. More complete financial results are detailed in the financial tables below.

MORE ON THIS TOPIC